Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study

다국어 초록 (Multilingual Abstract)

Objective: The molecular classification system of endometrial carcinoma (EC) in ‘The Cancer Genome Atlas’ is widely acknowledged for its prognostic utility. Subsequently, more simplified classification system that incorporate DNA polymerase epsilon (POLE) exonuclease domain mutations, mismatch repair deficiencies (MMRd), and abnormal p53 (P53abn) has also demonstrated its clinical utility. These classifications helped identifying a ‘POLE ultramutated’ (POLEmut) category of patients, most of whom show excellent prognoses despite having high-grade ECs. We aimed to investigate the clinicopathological and molecular characteristics of high-grade ECs with POLEmut.
Methods: We investigated 414 patients with high-grade ECs (including endometrioid carcinomas grade 3, serous carcinomas, clear cell carcinomas, mixed carcinomas, undifferentiated and dedifferentiated carcinomas, and carcinosarcomas) by sequencing and immunohistochemical staining.
Results: Forty-three tumors (10.4%) were classified as POLEmut, including 2 with new, possibly pathogenic POLE mutations at P286C and L424V. These patients had very good prognoses except for 1 with stage IV disease and residual tumor. Eleven patients in this group also had P53abn and 4 had MMRd; molecular analysis revealed that patients with synchronous POLE pathogenic mutation and other mutations had a POLEmut or MMRd phenotype; survival analysis found no difference in prognosis between these patient categories. The prognoses of patients in the POLEmut EC group were not significantly influenced by treatment or risk category.
Conclusions: Patients with high-grade EC exhibiting POLEmut have very good clinical outcomes, and should be identified urgently in daily work owing to their conflicting morphology. Our findings also provide guidance on subclassifying ECs with poor histological appearance.

참고문헌 (Reference)

1 Singh N, "p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies" 250 : 336-345, 2020

2 Alexandrov LB, "Signatures of mutational processes in human cancer" 500 : 415-421, 2013

3 Church DN, "Prognostic significance of POLE proofreading mutations in endometrial cancer" 107 : 402-, 2014

4 Hodel KP, "POLE mutation spectra are shaped by the mutant allele identity, its abundance, and mismatch repair status" 78 : 1166-1177, 2020

5 Talhouk A, "Molecular subtype not immune response drives outcomes in endometrial carcinoma" 25 : 2537-2548, 2019

6 Bosse T, "Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups" 42 : 561-568, 2018

7 León-Castillo A, "Interpretation of somatic POLE mutations in endometrial carcinoma" 250 : 323-335, 2020

8 Cancer Genome Atlas Research Network, "Integrated genomic characterization of endometrial carcinoma" 497 : 67-73, 2013

9 Vermij L, "Incorporation of molecular characteristics into endometrial cancer management" 76 : 52-63, 2020

10 Yano M, "Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma" 32 : 1023-1031, 2019

11 Palles C, "Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas" 45 : 136-144, 2013

12 Kommoss S, "Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series" 29 : 1180-1188, 2018

13 WHO Classification of Tumours Editorial Board, "Female genital tumours. WHO classification of tumours, 5th edition, volume 4" World Health Organization 252-266, 2020

14 Shinbrot E, "Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication" 24 : 1740-1750, 2014

15 McAlpine JN, "Evaluation of treatment effects in patients with endometrial cancer and POLE mutations : an individual patient data meta-analysis" 127 : 2409-2422, 2021

16 McConechy MK, "Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis" 22 : 2865-2873, 2016

17 Colombo N, "ESMO-ESGOESTRO Consensus Conference on Endometrial Cancer : diagnosis, treatment and follow-up" 27 : 16-41, 2016

18 Concin N, "ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma" 31 : 12-39, 2021

19 Haradhvala NJ, "Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair" 9 : 1746-, 2018

20 Yu S, "Detection of POLE subtypes in high-grade endometrioid carcinoma by BaseScope-ISH assay" 9 : 831-, 2019

21 Alexandrov LB, "Deciphering signatures of mutational processes operative in human cancer" 3 : 246-259, 2013

22 Church DN, "DNA polymerase ε and δexonuclease domain mutations in endometrial cancer" 22 : 2820-2828, 2013

23 Talhouk A, "Confirmation of ProMisE : a simple, genomics-based clinical classifier for endometrial cancer" 123 : 802-813, 2017

24 He Y, "Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: a systematic review and meta-analysis" 99 : e19281-, 2020

25 León-Castillo A, "Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas" 250 : 312-322, 2020

26 Stasenko M, "Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer" 156 : 194-202, 2020

27 Van Gool IC, "Adjuvant treatment for POLE proofreading domain-mutant cancers : sensitivity to radiotherapy, chemotherapy, and nucleoside analogues" 24 : 3197-3203, 2018